All patients were diagnosed with PD or DLB (all patients were asked to use concomitant levodopa preparations (including DCI combination drugs), and patients can continue to use other anti-Parkinson drugs such as dopamine agonists (DA), monoamine oxidase type B (MAO-B) inhibitors, amantadine or droxodopa, and anticholinergics during the study period. Here, MAOB is linked to Parkinson disease.